Financial Data and Key Metrics Changes - In 2025, the company's revenue increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [20] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income [21] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22] - Administrative expenses were CNY 199.5 million, a decline of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and organizational optimization [23] - As of December 31, 2025, cash and cash equivalents were CNY 1,941 million, expected to support operations beyond 2028 [22] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV functional cure program, which remains its top clinical priority, with key data reported and studies progressing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][5] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, establishing labs in Beijing and Shanghai to support early-stage drug discovery [9][36] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a strategic approach to market engagement [32][38] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses to approximately one quarter of their original level [5] - The strategy includes a disciplined partnering approach for non-HBV assets while focusing on areas with the strongest near-term opportunities [10][11] - The company plans to introduce new programs from its discovery platform and define its development strategy around them [24][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, expecting important data to emerge later this year to inform the next stage of development [40] - The company is aware of the competitive landscape and aims to differentiate its offerings while exploring the potential of its expanded discovery capabilities [29][36] Other Important Information - The company has made significant investments in building its internal research capabilities and integrating AI-enabled discovery tools into its workflow [8][9] - The company is open to both internal development and partnerships for its discovery programs, depending on expertise and market potential [38] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in the ENRICH study, and a 10% or better response in the ENHANCE study compared to previous results [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is expanding beyond infectious diseases to include chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32]

Group 1: Market Movements - Several biotech and healthcare companies experienced notable gains in after-hours trading, driven by earnings updates, guidance announcements, and broader investor sentiment [1] - FibroBiologics, Inc. (FBLG) led with a 7.68% increase, closing at $0.41, suggesting speculative interest or technical momentum [1] - Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary results for Q4 and full year 2025, along with revenue guidance for Q1 2026 [2] - Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49, continuing a trend of volatility despite no new news [2] - Revvity, Inc. (RVTY) gained 4.92% to close at $109.00, with investors likely reacting to a previous collaboration announcement with Eli Lilly [3] - Option Care Health, Inc. (OPCH) rose 3.28% to $33.11 after releasing preliminary unaudited financial results for Q4 and full year 2025, along with guidance for 2026 [4] - Actinium Pharmaceuticals, Inc. (ATNM) added 3.02% to close at $1.34, reflecting investor activity in the broader biotech sector [4] - Design Therapeutics, Inc. (DSGN) gained 1.97% to $9.30, indicating continued interest despite no specific news [5] Group 2: Company-Specific Developments - FibroBiologics, Inc. (FBLG) showed a significant rise without any company-specific news, indicating potential speculative interest [1] - Nyxoah SA (NYXH) provided revenue guidance for Q1 2026, which bolstered investor confidence in its growth trajectory [2] - Revvity, Inc. (RVTY) is expanding access to predictive models through a collaboration with Eli Lilly, aimed at accelerating AI-enabled drug discovery [3] - Option Care Health, Inc. (OPCH) released preliminary financial results and guidance, contributing to its positive after-hours reaction [4]

Industry Overview - The biotech sector experienced a significant recovery in 2025, with the Nasdaq Biotechnology Index increasing by 33.8% [2] - Initial concerns regarding potential high tariffs negatively impacted the industry, but investor sentiment rebounded sharply, leading to a notable recovery [2] Drug Approvals and M&A Activity - The rally in the biotech sector was fueled by a consistent stream of new drug approvals, positive pipeline and regulatory updates, and an increase in mergers and acquisitions (M&A) activity [3] - The FDA approved over 44 drugs in 2025, indicating renewed momentum in the industry, which is expected to continue into 2026 due to investor optimism surrounding key drug approvals and innovation [4] Key Biotech Stocks - Three biotech stocks are highlighted for their potential high-impact catalysts in 2026: Denali Therapeutics (DNLI), Nuvalent, Inc. (NUVL), and Vanda Pharmaceuticals (VNDA) [5] - All three companies showed strong performance in the latter half of 2025, a trend likely to persist into 2026 due to favorable regulatory developments and promising pipeline updates [5] Denali Therapeutics - Denali has a robust pipeline targeting neurodegenerative diseases, including DNL310 (tividenofuspalfa), an enzyme replacement therapy for Hunter syndrome designed to cross the blood-brain barrier [7] - The FDA has extended the review timeline for Denali's BLA for tividenofuspalfa to April 5, 2026, following the submission of updated clinical information [11] - Denali's pipeline also includes candidates for Sanfilippo syndrome, Parkinson's disease, and ulcerative colitis [13] Nuvalent, Inc. - Nuvalent focuses on developing targeted cancer therapies, with its lead candidate zidesamtinib aimed at ROS1-positive non-small cell lung cancer (NSCLC) [14][15] - The FDA has accepted Nuvalent's NDA for zidesamtinib, with a target action date of September 18, 2026 [16] - The company also reported positive data for its second lead candidate, neladalkib, in advanced ALK-positive NSCLC [17] Vanda Pharmaceuticals - Vanda is dedicated to developing therapies for unmet medical needs, with its candidate imsidolimab targeting generalized pustular psoriasis (GPP) [18][19] - The company has requested priority review for imsidolimab, which could lead to FDA approval as early as mid-2026 [20] - Vanda has multiple regulatory catalysts ahead, including reviews for Bysanti and tradipitant, with target action dates in early 2026 [22]

Financial Data and Key Metrics Changes - The company reported a record revenue of $99 million for Q4, representing a 17% year-over-year increase and marking the 11th consecutive quarter of growth [7] - For the full fiscal year 2025, revenue reached $376.6 million, a growth of 20% compared to fiscal 2024 [7][23] - Gross margin for Q4 was 51.3%, and for the full year, it was 50.7%, an increase from 42.6% in fiscal 2024 [7][23] Business Line Data and Key Metrics Changes - Synbio revenue for Q4 was $39.5 million, up 17% year-over-year, and for the full year, it increased to $145 million from $123.5 million in fiscal 2024 [8][23] - NGS revenue for Q4 grew to approximately $53 million, a 16% increase year-over-year, with full-year revenue at $208.1 million, reflecting a 23% growth [12][24] - Biopharma revenue for Q4 was $6.4 million, a 22% increase year-over-year, with full-year revenue at $23.5 million, a 15% growth [14][24] Market Data and Key Metrics Changes - Revenue from the Americas increased to approximately $57.3 million in Q4, a 9% year-over-year growth, while EMEA revenue rose to $34.6 million, a 35% increase [25] - APAC revenue increased to $7.2 million in Q4, a 9% year-over-year growth [25] Company Strategy and Development Direction - The company plans to combine Synbio and Biopharma revenue reporting under the term "DNA synthesis and protein solutions" to better reflect its customer base [16] - A focus on AI-driven drug discovery is expected to drive future growth, with significant orders from customers in this area [10][29] - The introduction of the MRD Express product is aimed at enhancing cancer diagnostics and treatment, with a commercial launch expected in early 2026 [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth opportunities, particularly in AI-enabled drug discovery and the integration of Synbio and Biopharma services [10][32] - The company anticipates total revenues for fiscal 2026 to be between $425 million and $435 million, reflecting a growth of approximately 13% to 15.5% year-over-year [29] Other Important Information - The company ended fiscal 2025 with cash, cash equivalents, and short-term investments of approximately $232.4 million [28] - Adjusted EBITDA for Q4 was a loss of approximately $7.8 million, an improvement of $9.2 million compared to Q4 of fiscal 2024 [27] Q&A Session Summary Question: On gross margins and pricing - Management indicated that while they expect to maintain strong gross margins, specific customer mix may influence quarterly results [36][37] Question: NGS growth expectations - Management expects NGS growth to return to 20% by Q4, driven by customer transitions and new product introductions [38] Question: Sustainability of AI-driven biopharma orders - Management remains optimistic about the biopharma business, highlighting the close ties to Synbio offerings and the potential of AI [40][41] Question: Guidance for gross margins and NGS portfolio - Management anticipates improvements in gross margins throughout the year, driven by revenue growth and continuous process improvements [43][44] Question: Market opportunity definition - Management acknowledged the need for clearer market definitions and metrics to help investors understand growth potential [59][62]

Core Insights - Recursion reported business updates and financial results for Q3 2025, highlighting progress in its internal pipeline and strategic partnerships, with a strong cash position extending through the end of 2027 [1][3][19] Business Highlights - The company achieved over $500 million in upfront and milestone payments from partnerships, including a recent $30 million milestone from Roche and Genentech for a whole-genome map of microglial immune cells [3][8][12] - Recursion's internal pipeline includes several programs in oncology and rare diseases, with notable candidates such as REC-617 for advanced solid tumors and REC-7735 for HR+ breast cancer [4][6][13] - The company is advancing its clinical programs, with REC-4881 in the TUPELO study and REC-617 entering combination studies [6][13] Financial Performance - Total revenue for Q3 2025 was $5.2 million, a decrease from $26.1 million in Q3 2024, primarily due to the timing of milestone payments [19][24] - Research and development expenses increased to $121.1 million in Q3 2025 from $74.6 million in Q3 2024, driven by acquisitions and business combinations [19][20] - The net loss for Q3 2025 was $162.3 million, compared to a net loss of $95.8 million in Q3 2024, reflecting increased operational costs [25][26] Cash Position - As of October 9, 2025, Recursion had approximately $785 million in cash and cash equivalents, providing a runway through the end of 2027 without additional financing [8][19] - The company reported a cash position of $667.1 million as of September 30, 2025, an increase from $603.0 million at the end of 2024 [19][28] Strategic Partnerships - Recursion's collaboration with Roche and Genentech focuses on neuroscience and oncology, with ongoing projects and milestones expected to exceed $10 billion in potential future payments [12][18] - The partnership with Sanofi aims to develop up to 15 best-in-class programs across oncology and immunology, with significant milestone payment potential [18][19]